Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Adebrelimab, Nab-Paclitaxel and Low-Dose RT in Early-Stage Oral SCC
NCT07007364Phase 2Recruiting
- Start
- Jun 2025
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in oral squamous cell carcinoma (OSCC). Started Jun 2025; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT07007364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07007364.